Main Article Content



Diabetes mellitus is one of the most common non-communicable disease world-wide. There are many groups of drugs available for the treatment of type 2 diabetes mellitus. we use these drugs as monotherapy or in combination to maintain normoglycemia. Because of paucity of published reports in the Indian literature regarding the pattern of use, efficacy, safety, tolerability of comparison of therapy of metformin and combination of metformin and glibenclamide, the present study was taken up.


To study the comparison of efficacy, safety and tolerability of metformin and combination of metformin and glibenclamide in achieving normal blood glucose level in type 2 diabetes mellitus.

Materials and methods

100 properly selected subjects with type 2 diabetes mellitus were included for the present study. The medication were used empirically as monotherapy or fixed dose combination, OD or BID in a continuation manner after the meals. Blood glucose level was measured at the baseline and daily afterwards for one month using standard techniques. The data collected was analyzed statistically using descriptive statistics. Tolerability and patient compliance for the prescribed medications were also assessed during the follow up visits.


Combination therapy reported to control the blood glucose level more efficiently as compared to metformin monotherapy at the end of the study, as 96% of subjects showed normoglycemia as compared to metformin (70%). Also, incidence of hyperglycemic episodes were less in combination therapy.  Subjects with combination therapy reported more side effects compared to metformin alone therapy. The patient compliance for the prescribed medications was excellent.

Interpretation and Conclusion

Blood glucose level can be effectively maintained under normal limits in Type 2 DM, with combination therapy as compared to monotherapy of metformin.


Diabetes mellitus Metformin Glibenclamide

Article Details

How to Cite
Dr. Syed Wasif, & Dr. Veeresh Salgar. (2021). An prospective and observational study of comparison of efficacy and tolerability between metformin and combination of metformin and glibenclamide in the maintence therapy of type 2 diabetes mellitus in a tertiary care hospital. International Journal of Research in Pharmacology & Pharmacotherapeutics, 7(1), 69-79. Retrieved from


  1. Ahlquist D, Camilleri M editors. Diabetes Mellitus. In: Harrisons: Principles of internal medicine. McGraw Hill companies: 19, 2016, 640-650.
  2. [2]. Mcphee SJ, Papadakis MA. Diabetes Mellitus and Hypoglycemia. In: Current Medical Diagnosis and Treatment.McGraw Hill companies: 2008.
  3. [3]. Tripati KD. Insulin, Oral Hypoglycaemic drugs and Glucagon. In. Essentials of Medical Pharmacology. Jaypee brothers medical publishers.7, 2011.
  4. [4]. Brunton LL, Chabner BA, Knollmann BC, editors. Endocrine Pancreas and Pharmacotherapy of Daibetes Mellitus and Hypoglycaemia. In: Goodman & Gilman’s The Pharmacological Basis of Therapeutics. New York: McGraw-Hill Companies; 13, 2017.
  5. [5]. Sharma HL, Sharma KK. Insulin and Other Antidiabetic drugs. In: Principles of Pharmacology. Paras medical publisher. P 2, 626- 640.
  6. [6]. Katzung, B.G., Masters, S.B., and Trevor, A.J Basic and Clinical Pharmacology. New York: Mc Graw-Hill Medical 13, 2015.
  7. [7]. Satoskar RS, Rage NN, Bhandarkar SD. Insulin and Oral Hypoglycaemic drugs. In: Pharmacology and Pharmacotherapeutics. P.22, 874 – 906.
  8. [8]. American Diabetes Association, Diabetes Care 40(1), 2017, S11-S24.
  9. [9]. Brunetti P, et al. Effects of two different glibenclamide dose-strengths in the fixed combination with metformin in patients with poorly controlled T2DM: a double blind, prospective, randomised, cross-over clinical trial. Diabetes Nutr Metab. 17(6), 2004, 350-7.
  10. [10]. Garber A, et al. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 8(2), 2006, 156-63.
  11. [11]. Rosenstock J, et al.Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 8(6), 2006, 650-60.
  12. [12]. Waugh N, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 14(36), 2010, 1-248. doi: 10.3310/hta14360.
  13. [13]. Lamos EM, et al. Combination of glibenclamide-metformin HCl for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother. 13(17), 2012, 2545-54 doi: 10.1517/14656566.2012.738196. Epub 2012.
  14. [14]. Morgan CL, et al. Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study. Diabetes Obes Metab. 16(10), 2014, 957-62. doi: 10.1111/dom.12302. Epub 2014.
  15. [15]. Morgan CL, et al. Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality. Diabetes Obes Metab. 16(10), 2014, 977-83. doi: 10.1111/dom.12306. Epub 2014.
  16. [16]. Jiang YF, et al. Comparative efficacy and safety of OADs in management of GDM: network meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 100(5), 2015, 2071-80. doi: 10.1210/jc.2014-4403. Epub 2015.
  17. [17]. Wang JS, et al. Glycemic excursions are positively associated with HbA1c reduction from baseline after treatment with acarbose in patients with type 2 diabetes on metformin monotherapy. J Diabetes. 9(3), 2017, 248-255. doi: 10.1111/1753-0407.12406. Epub 2016.
  18. [18]. Nachum Z, et al. Glyburide versus Metformin and their Combination for the treatment of Gestational Diabetes Mellitus: A Randomized Study. Diabetes Care. 40(3), 2017, 332-337. doi: 10.2337/dc16-2307. Epub 2017.
  19. [19]. Davison JA, et al. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy. Clin Ther. 29(9), 2007, 1900-14.
  20. [20]. Jennifer N, Jose C. An upadate on the pharmacogenomics of metformin: progress, problems and potential. Pharmacogenomics. 15(4), 2014, 529–539. doi: 10.2217/pgs.14.21.
  21. [21]. Lee EY, et al. Association between Metformin Use and Risk of Lactic Acidosis or Elevated Lactate Concentration in Type 2 Diabetes. Yonsei Med J. 58(2), 2017, 312–318.
  22. [22]. Cefalu WT, et al. Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management. Diabetes Care 37(9), 2014, 2647–2659.
  23. [23]. Viollet B, et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 122(6), 2012, 253–270.
  24. [24]. Unnikrishnan R, Shah VN, Mohan V. Challenges in diagnosis and management of diabetes in the young.Clin Diabetes Endocrinol. 2, 2016, 18.
  25. [25]. Aschner P, et al. Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults. Clomb Med (cali). 47(2), 2016, 109–131.
  26. [26]. Tosi F, et al. Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study. Metabolism. 52(7), 2003, 862-7.
  27. [27]. Mearns ES, et al. Comparative Efficacy and Safety of Antidiabetic Drug Regimens Added to Metformin Monotherapy in Patients with Type 2 Diabetes: A Network Meta-Analysis. PLoS One. 10(4), 2015, e0125879.
  28. [28]. Liang H, et al. Comparative efficacy and safety of oral antidiabetic drugs and insulin in treating gestational diabetes mellitus. Medicine (Baltimore). 96(38), 2017, e7939.
  29. [29]. Lewin A, et al. Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study. Clin Ther. 29(5), 2007, 844-55.
  30. [30]. Gu S, et al. Comparison of Glucose Lowering Effect of Metformin and Acarbose in Type 2 Diabetes Mellitus: A Meta-Analysis. PLoS One. 10(5), 2015, e0126704.
  31. [31]. Chen L, et al. Comparison of glyburide and insulin in the management of gestational diabetes: A meta-analysis. PLoS One. 12(8), 2017, e0182488.
  32. [32]. Joy NG, et al. Counterregulatory Responses to Hypoglycemia Differ between Glimepiride and Glyburide in Non Diabetic Individuals. Metabolism. 64(6), 2015, 729–737.
  33. [33]. Sun J, et al. Deciphering Signaling Pathway Networks to Understand the Molecular Mechanisms of Metformin Action. PLoS Comput Biol. 11(6), 2015, e1004202.
  34. [34]. Gorter KJ, et al. Diabetes: glycaemic control in type 2 (drug treatments). BMJ Clin Evid. 11, 2012, 2012. pii: 0609.
  35. [35]. Williams LK, et al. Differing Effects of Metformin on Glycemic Control by Race-Ethnicity. J Clin Endocrinol Metab. 99(9), 2014, 3160–3168.
  36. [36]. Fung CSC, et al. Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients. Cardiovasc Diabetol. 14, 2015, 137.
  37. [37]. Williams HD, et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin. 25(3), 2009, 569-83. doi:10.1185/03007990802705679 .
  38. [38]. Lukashevich V, et al. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes Obes Metab. 16(5), 2014, 403–409.
  39. [39]. Chang C, Sakaguchi M, Dolin P. Epidemiology of lactic acidosis in type 2 diabetes patients with metformin in Japan. Pharmacoepidemiol Drug Saf. 25(10), 2016, 1196–1203.
  40. [40]. Lachin JM, et al. Factors Associated With Diabetes Onset During Metformin Versus Placebo Therapy in the Diabetes Prevention Program. Diabetes. 56(4), 2007, 1153–1159.
  41. [41]. Davidson JA, Sloan L. Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview. Adv Ther. 34(1), 2017, 41–59.
  42. [42]. Patterson AG, et al. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ. 350, 2015, h102.
  43. [43]. Nachum Z, et al. Glyburide Versus Metformin and Their Combination for the Treatment of Gestational Diabetes Mellitus: A Randomized Controlled Study. Diabetes Care. 40(3), 2017, 332-337. doi: 10.2337/dc16-2307. Epub 2017.
  44. [44]. Dailey GE, et al. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med. 15, 2004, 116(4):223-9.
  45. [45]. Andersen SE, Christensen M. Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis. Br J Clin Pharmacol. 82(5), 2016, 1291-1302. doi: 10.1111/bcp.13059. Epub 2016.
  46. [46]. Balijepalli C, et al. Hypoglycemia: a review of definitions used in clinical trials evaluating antihyperglycemic drugs for diabetes. Clin Epidemiol. 23, 2017, 9:291-296. doi: 10.2147/CLEP.S129268. eCollection 2017.
  47. [47]. Haak T, et al. Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study. Int J Clin Pract. 67(12), 2013, 1283–1293.
  48. [48]. Lundquist I, et al. Metformin Ameliorates Dysfunctional Traits of Glibenclamide- and Glucose-Induced Insulin Secretion by Suppression of Imposed Overactivity of the Islet Nitric Oxide Synthase-NO System. PLoS One. 11(11), 2016, e0165668.
  49. [49]. Plata PA, et al. Metformin effects revisited. Diabetes Res Clin Pract. 2012 Jan; 95(1): 1–9.
  50. [50]. Setter SM, et al. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ther. 25(12), 2003, 2991-3026.
  51. [51]. Inzucchi SE, et al. Metformin in Patients With Type 2 Diabetes and Kidney Disease. JAMA. 24-31, 2014, 312(24): 2668–2675.
  52. [52]. Lee KT, et al. Metformin is associated with fewer major adverse cardiac events among patients with a new diagnosis of type 2 diabetes mellitus. Medicine (Baltimore). 96(28), 2017, e7507.
  53. [53]. Rojas LBA, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 5, 2013, 6.
  54. [54]. Barco SD, et al. Metformin: Multi-faceted protection against cancer. Oncotarget. 2(12), 2011, 896–917.
  55. [55]. Hatoum D, McGowan EM. Recent Advances in the Use of Metformin: Can Treating Diabetes Prevent Breast Cancer?. Biomed Res Int. 2015, 2015, 548436.